Arbutus Biopharma Corporation (ABUS) Getting Somewhat Favorable News Coverage, Report Finds
Media coverage about Arbutus Biopharma Corporation (NASDAQ:ABUS) has been trending somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Arbutus Biopharma Corporation earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.2408155083312 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news stories that may have impacted Accern’s analysis:
- Arbutus Biopharma Corporation (NASDAQ:ABUS) Rating Reiterated by Chardan Capital (americanbankingnews.com)
- Arbutus Biopharma Corp’s (ABUS) CEO Mark Murray on Q2 2017 Results – Earnings Call Transcript – Seeking Alpha (seekingalpha.com)
- Arbutus Announces Corporate Update and Second Quarter 2017 Financial Results – GlobeNewswire (press release) (globenewswire.com)
- Edited Transcript of ABUS earnings conference call or presentation 3-Aug-17 8:30pm GMT (finance.yahoo.com)
- Zacks: Analysts Expect Arbutus Biopharma Corporation (NASDAQ:ABUS) Will Announce Quarterly Sales of $680,000.00 (americanbankingnews.com)
Several analysts recently commented on the company. Chardan Capital reiterated a “buy” rating on shares of Arbutus Biopharma Corporation in a report on Monday. Zacks Investment Research upgraded Arbutus Biopharma Corporation from a “sell” rating to a “hold” rating in a report on Monday, July 10th. Finally, Ladenburg Thalmann Financial Services started coverage on Arbutus Biopharma Corporation in a report on Friday, June 2nd. They set a “buy” rating and a $32.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Arbutus Biopharma Corporation has an average rating of “Buy” and an average target price of $11.65.
Arbutus Biopharma Corporation (ABUS) remained flat at $3.55 during trading on Tuesday. The company had a trading volume of 13,401 shares. Arbutus Biopharma Corporation has a 12-month low of $2.35 and a 12-month high of $4.49. The company’s market capitalization is $195.34 million. The stock’s 50 day moving average price is $3.67 and its 200 day moving average price is $3.22.
COPYRIGHT VIOLATION NOTICE: “Arbutus Biopharma Corporation (ABUS) Getting Somewhat Favorable News Coverage, Report Finds” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/08/arbutus-biopharma-corporation-abus-getting-somewhat-favorable-news-coverage-report-finds.html.
Arbutus Biopharma Corporation Company Profile
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.